Market Place
Sourcing Support
Merz Therapeutics Plans US Workforce Growth After $185M Asset Purchase
12 Jul 2024 //
FIERCE PHARMA
Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
11 Jul 2024 //
PHARMACEUTICAL-TECHNOLOGY
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
10 Jul 2024 //
BUSINESSWIRE
Acorda fights on with new Inbrija ad ahead of bankruptcy sale
04 Jun 2024 //
FIERCE PHARMA
US FDA declines to approve Supernus` Parkinson`s combination again
09 Apr 2024 //
REUTERS
Acorda Therapeutics Announces Nasdaq Delisting Notification
03 Apr 2024 //
BUSINESSWIRE
Acorda files for bankruptcy, inks $185M asset deal to Merz
03 Apr 2024 //
FIERCE PHARMA
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call
01 Apr 2024 //
BUSINESSWIRE
Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
01 Apr 2024 //
BUSINESSWIRE
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
12 Jan 2024 //
FIERCE PHARMA
Acorda to Regain Global Commercialization Rights to FAMPYRA® by January 2025
11 Jan 2024 //
BUSINESSWIRE
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Acorda Announces Biopas Laboratories Submission to Regulatory Agencies
06 Nov 2023 //
BUSINESSWIRE
Acorda Third Quarter 2023 Update
06 Nov 2023 //
BUSINESSWIRE
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Acorda Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
02 Aug 2023 //
BUSINESSWIRE
Tom Burns Elected to the Acorda Therapeutics Board of Directors
28 Jun 2023 //
BUSINESSWIRE
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
26 Jun 2023 //
BUSINESSWIRE
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
02 Jun 2023 //
BUSINESSWIRE
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
31 May 2023 //
BUSINESSWIRE
Acorda CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
30 May 2023 //
BUSINESSWIRE
Chance Pharma & Acorda Announce Agreement to Provide INBRIJA
08 May 2023 //
PR NEWSWIRE
Acorda Therapeutics to Present INBRIJA® Data at American Academy of Neurology
24 Apr 2023 //
BUSINESSWIRE
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
03 Apr 2023 //
BUSINESSWIRE
Acorda CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
27 Mar 2023 //
BUSINESSWIRE
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
BUSINESSWIRE
ESTEVE Launches INBRIJA® in Spain
07 Mar 2023 //
BUSINESSWIRE
Acorda Fourth Quarter/Year End 2022 Update
06 Mar 2023 //
BUSINESSWIRE
Acorda Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
14 Feb 2023 //
BUSINESSWIRE
Acorda Announces Agreement with Catalent for Long-Term Global Supply of INBRIJA®
05 Jan 2023 //
BUSINESSWIRE
Acorda Therapeutics Receives Nasdaq Listing Determination Letter
20 Dec 2022 //
BUSINESSWIRE
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal
11 Nov 2022 //
BUSINESSWIRE
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
04 Nov 2022 //
BUSINESSWIRE
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
01 Nov 2022 //
BUSINESSWIRE
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
27 Oct 2022 //
BUSINESSWIRE
Acorda Third Quarter 2022 Update: Webcast Scheduled for November
25 Oct 2022 //
BUSINESSWIRE
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
21 Oct 2022 //
BUSINESSWIRE
Acorda Announces $16.5M Award & Royalty/Supply Relief in AMPYRA Arbitration Case
16 Oct 2022 //
BUSINESSWIRE
Acorda Withdraws Proposal to Increase Authorized Shares
10 Oct 2022 //
BUSINESSWIRE
Acorda to Present at H.C. Wainwright 24th Annual Global Investment Conference
08 Sep 2022 //
BUSINESSWIRE
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
29 Aug 2022 //
BUSINESSWIRE
Acorda Therapeutics Announces Resignation of Chief Operating Officer
19 Aug 2022 //
BUSINESSWIRE
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled
28 Jul 2022 //
BUSINESSWIRE
NICE opts to reject Acorda’s MS drug Fampyra
22 Jun 2022 //
PHARMATIMES
Esteve Launches INBRIJA® in Germany
16 Jun 2022 //
BUSINESSWIRE
Acorda and Biopas Laboratories Announce Agreement to Commercialize INBRIJA
11 May 2022 //
BUSINESSWIRE
Acorda Q1 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
04 May 2022 //
BUSINESSWIRE
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
09 Mar 2022 //
BUSINESSWIRE
Acorda Fourth Quarter/Year End 2021 Update on March 9
24 Feb 2022 //
BUSINESSWIRE
Acorda CMO hits the exit, landing Pharnext job
25 Nov 2021 //
FIERCEBIOTECH
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA in Germany
09 Nov 2021 //
BIOSPACE
Acorda Reports Q3 2021 Financial Results, Additions to Leadership Team
09 Nov 2021 //
BUSINESSWIRE
Acorda slashes jobs again as generics hamper sales of MS drug
10 Sep 2021 //
FIERCEPHARMA
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
09 Sep 2021 //
BUSINESSWIRE
Struggling Acorda team brings out the budget axe again to chop away costs
09 Sep 2021 //
ENDPTS
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
Acorda Second Quarter 2021 Update
30 Jul 2021 //
BUSINESS WIRE
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
23 Jul 2021 //
BUSINESSWIRE
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
16 Jun 2021 //
BUSINESSWIRE
